CollPlant Biotechnologies (CLGN) Accumulated Expenses (2018 - 2025)

CollPlant Biotechnologies (CLGN) has 8 years of Accumulated Expenses data on file, last reported at $1.2 million in Q4 2025.

• Quarterly Accumulated Expenses fell 3.55% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 3.55% YoY) and the FY2025 annual result came in at $1.2 million, down 3.55% from the prior year.
• Accumulated Expenses climbed to $1.2 million in Q4 2025, from $1.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.7 million in Q1 2024 to a low of $957000.0 in Q3 2021.
• A 5-year average of $1.3 million and a median of $1.3 million in 2023 frame the typical range for Accumulated Expenses.
• The widest YoY moves for Accumulated Expenses: up 97.62% in 2021, down 41.89% in 2021.
• Tracing CLGN's Accumulated Expenses over 5 years: stood at $1.4 million in 2021, then grew by 0.98% to $1.4 million in 2022, then rose by 14.14% to $1.6 million in 2023, then decreased by 21.43% to $1.3 million in 2024, then dropped by 3.55% to $1.2 million in 2025.
• The last three Accumulated Expenses figures came in at $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.